Ioflupane (I-123)
Updates to Article Attributes
Body
was changed:
I123 Ioflupane is a radiopharmaceutical for the diagnosis of Parkinson disease and its differential diagnoses.
Characteristics
-
Iodineiodine-123 is a cyclotron product -
Physicalphysical half-life is 13.22 hours -
Thepredominant energy of its gamma spectrum is 159 keV
Ioflupane is the International non-proprietaryinternational nonproprietary name of a phenyltropane compound, a cocaine analogue. Ioflupane has a high affinity for presynaptic dopamine transporters which are abundant in the striatal region.
I-123 Ioflupane is available in Europe and North America where it is marketed under the tradenametrade name DaTSCANTM.
Uses, doses and timing
- as a cyclotron product, the solution is supplied ready to inject
- the dose reference activity of I-123 Ioflupane is 185 MBq
- administration is intravenous
- thyroid blocking with 120 mg
potassionpotassium iodide 2 hours before and 24 hours after the injection is recommended - SPECT scanning typically occurs 3-6 hours after injection
.
-<p><strong>I<sup>123</sup> Ioflupane </strong>is a <a href="/articles/radiopharmaceuticals" title="radiopharmaceutical">radiopharmaceutical</a> for the diagnosis of <a href="/articles/parkinson-disease" title="Parkinson disease">Parkinson disease</a> and its differential diagnoses.</p><h4>Characteristics</h4><ul>-<li>Iodine-123 is a <a href="/articles/cyclotron" title="cyclotron">cyclotron</a> product</li>-<li>Physical half-life is 13.22 hours</li>-<li>The predominant energy of its gamma spectrum is 159 keV</li>-</ul><p>Ioflupane is the International non-proprietary name of a phenyltropane compound, a cocaine analogue. Ioflupane has a high affinity for presynaptic dopamine transporters which are abundant in the striatal region.</p><p>I-123 Ioflupane is available in Europe and North America where it is marketed under the tradename DaTSCAN<sup>TM</sup></p><h4>Uses, doses and timing</h4><ul>-<li>as a cyclotron product, the solution is supplied ready to inject</li>-<li>the dose reference activity of I-123 Ioflupane is 185 MBq</li>-<li>administration is intravenous</li>-<li>thyroid blocking with 120 mg potassion iodide 2 hours before and 24 hours after the injection is recommended</li>-<li>SPECT scanning typically occurs 3-6 hours after injection.</li>- +<p><strong>I<sup>123</sup> Ioflupane </strong>is a <a href="/articles/radiopharmaceuticals">radiopharmaceutical</a> for the diagnosis of <a href="/articles/parkinson-disease">Parkinson disease</a> and its differential diagnoses.</p><h4>Characteristics</h4><ul>
- +<li>iodine-123 is a <a href="/articles/cyclotron">cyclotron</a> product</li>
- +<li>physical half-life is 13.22 hours</li>
- +<li>predominant energy of its gamma spectrum is 159 keV</li>
- +</ul><p>Ioflupane is the international nonproprietary name of a phenyltropane compound, a cocaine analogue. Ioflupane has a high affinity for presynaptic dopamine transporters which are abundant in the striatal region.</p><p>I-123 Ioflupane is available in Europe and North America where it is marketed under the trade name DaTSCAN<sup>TM</sup>.</p><h4>Uses, doses and timing</h4><ul>
- +<li>as a cyclotron product, the solution is supplied ready to inject</li>
- +<li>the dose reference activity of I-123 Ioflupane is 185 MBq</li>
- +<li>administration is intravenous</li>
- +<li>thyroid blocking with 120 mg potassium iodide 2 hours before and 24 hours after the injection is recommended</li>
- +<li>SPECT scanning typically occurs 3-6 hours after injection</li>
References changed:
- 1. Seifert KD, Wiener JI. The impact of DaTscan on the diagnosis and management of movement disorders: A retrospective study. Am J Neurodegener Dis. 2013;2 (1): 29-34. <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601468">Free text at pubmed</a> - <a href="http://www.ncbi.nlm.nih.gov/pubmed/23515233">Pubmed citation</a><span class="auto"></span>
Tags changed:
- refs
- cases
Unable to process the form. Check for errors and try again.